Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 trial of dasiglucagon SC infusion in children with congenital hyperinsulinism
2017-004547-21Phase 3Unknown
- Sponsor
- Zealand Pharma
- Start
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dasiglucagon in congenital hyperinsulinism (HI), sponsored by Zealand Pharma. Primary endpoint: Primary endpoint - Treatment Period 1 hypoglycaemia event rate. Status: unknown.
02
Drugs
dasiglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on 2017-004547-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004547-21.